Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegafur/Temozolomide vs Tegafur/Temozolomide/Thalidomide in Advanced pNET
NCT03204019Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide in Pancreatic neuroendocrine tumor (PanNET) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
thalidomide
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT03204019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204019.